Search Results

Pharm Country

Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®

Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura ®.

July 5, 2022

·

7 min read

DelSiTech and Innovare Sign Licensing Agreement for the Development of a Long Acting HIV Therapy

DelSiTech Ltd, a Finnish drug delivery technology and drug development company and InnovareR&D, a leading Mexican pharmaceutical company, have signed a world-wide, exclusive licence agreement for the use of DelSiTech’s Silica Matrix drug delivery platform in the development and commercialisation of a long acting HIV therapy.

December 18, 2018

·

3 min read

DelSiTech Ltd Receives Significant Funding for Developing Long-Acting Injectables

DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced significant grant funding to support the development of long-acting controlled release formulations for family planning as well as for human immunodeficiency virus (HIV) antivirals, from the Bill & Melinda Gates Foundation.

May 21, 2019

·

2 min read

Business

DelSiTech and C-Tri Co. Ltd Sign a Collaboration Agreement to Develop Innovative Drug Delivery Technology Product for Oncology

DelSiTech and C-Tri Co. have signed a Partnership and Collaboration Agreement to develop long-acting controlled release formulations with significant commercial potential.

December 18, 2017

·

1 min read

DelSiTech Ltd Receives Funding for the Stabilization of Viral Vaccines

Awarded a grant for vaccine development by the Bill & Melinda Gates Foundation

October 30, 2018

·

2 min read

Business

DelSiTech And Bayer Partner To Develop Innovative Drug Delivery Technology For Ophthalmology

September 29, 2016

·

2 min read

Business

Bayer And DelSiTech Partner To Develop Innovative Drug Delivery Technology For Ophthalmology

September 29, 2016

·

3 min read

Business

DelSiTech Enters Into Research Collaboration With Orion Corporation

October 7, 2009

·

4 min read

BioForest

Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology

Visus Therapeutics Inc. announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration, two of the leading causes of blindness globally.

August 19, 2021

·

6 min read

Business

DelSiTech Signs License Agreement With Bayer Innovation

January 19, 2007

·

1 min read